TGFB1 and neoplasm: Nonetheless, the essential role for TGFβ in driving tumour progression is manifested in its capacity as a key determinant of the most aggressive molecular subtype of CRC, consensus molecular subtype 4 (CMS4), which is characterised by pro-tumourigenic stromal TGFβ signalling and aberrant EMT-pathway activation18.